[go: up one dir, main page]

WO2010012004A3 - Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence - Google Patents

Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence Download PDF

Info

Publication number
WO2010012004A3
WO2010012004A3 PCT/US2009/051880 US2009051880W WO2010012004A3 WO 2010012004 A3 WO2010012004 A3 WO 2010012004A3 US 2009051880 W US2009051880 W US 2009051880W WO 2010012004 A3 WO2010012004 A3 WO 2010012004A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
disease
alzheimer
amyoid
pathological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/051880
Other languages
French (fr)
Other versions
WO2010012004A2 (en
Inventor
Charles G. Glabe
Rakez Kayed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to US13/055,908 priority Critical patent/US20110200609A1/en
Publication of WO2010012004A2 publication Critical patent/WO2010012004A2/en
Publication of WO2010012004A3 publication Critical patent/WO2010012004A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Monoclonal antibody compositions, methods of production and use. The monoclonal antibodies are specific to conformational epitope(s) of a prefibrillar aggregate(s) which contribute to amyloid fibril formation in human or animal subjects who suffer from amyloid diseases (e.g., Alzheimer's Disease) and the hybridomas and monoclonal antibodies produced therefrom. The monoclonal antibodies are useable for immunization of human or animal subjects against Alzheimer's Disease or other amyloid diseases and/or for the diagnosis or detection of Alzheimer's Disease or other amyloid diseases. The monoclonal antibodies may be administered concomitantly or in combination with anti-inflammatory agents, such as gold or gold containing compounds, to decrease neural inflammation associated with amyloid diseases (e.g., Alzheimer's Disease).
PCT/US2009/051880 2002-09-12 2009-07-27 Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence Ceased WO2010012004A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/055,908 US20110200609A1 (en) 2002-09-12 2009-07-27 Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8385308P 2008-07-25 2008-07-25
US61/083,853 2008-07-25

Publications (2)

Publication Number Publication Date
WO2010012004A2 WO2010012004A2 (en) 2010-01-28
WO2010012004A3 true WO2010012004A3 (en) 2010-05-20

Family

ID=41570902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/051880 Ceased WO2010012004A2 (en) 2002-09-12 2009-07-27 Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence

Country Status (1)

Country Link
WO (1) WO2010012004A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009099176A1 (en) 2008-02-08 2009-08-13 Immunas Pharma, Inc. Antibody capable of binding specifically to aβ-oligomer, and use thereof
US8546532B2 (en) 2008-04-17 2013-10-01 Declion Pharmaceuticals, Inc. Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
DK2419447T3 (en) * 2009-04-17 2017-09-25 Immunas Pharma Inc ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
DK2462162T3 (en) 2009-08-06 2017-01-16 Immunas Pharma Inc Antibodies that specifically bind to A-beta oligomers and their use
ES2624835T3 (en) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Antibodies that specifically bind to the A beta oligomers and use thereof
CN102695546B (en) 2009-09-11 2014-09-10 前体生物药物股份公司 Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2020003043A (en) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Methods of detecting transthyretin.
EP3691447A4 (en) 2017-10-06 2021-08-11 Prothena Biosciences Limited ANTI-TRANSTHYRETINE ANTIBODIES
MX2020005433A (en) 2017-11-29 2020-08-27 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin.
CA3120066A1 (en) 2018-11-14 2020-05-22 University Of Kentucky Research Foundation Diagnosis of diabetes by detecting aggregated amylin in erythrocytes
JPWO2021006212A1 (en) * 2019-07-08 2021-01-14
WO2021035210A1 (en) * 2019-08-22 2021-02-25 The Regents Of The University Of California A single chain antibody that binds tau oligomers and inhibits seeding by pathological extracts from alzheimer's disease
CN115916347A (en) * 2020-04-21 2023-04-04 德克萨斯大学系统董事会 Antibodies against chitinase 3-like 1 and methods of use thereof
CN112540180B (en) * 2020-11-06 2022-03-29 华中科技大学 Sandwich ELISA kit for detection of human amyloid-β
CN112881708B (en) * 2021-01-19 2022-03-25 华中科技大学 Colloidal gold immunochromatographic test paper for detecting human amyloid-beta and preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024090A2 (en) * 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2005025516A2 (en) * 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024090A2 (en) * 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2005025516A2 (en) * 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
0'NUALLAIN B ET AL.: "Conformational Abs recognizing a generic amyloid fibril epitope.", PROC NATL ACAD SCI USA., vol. 99, no. 3, 5 February 2002 (2002-02-05), pages 1485 - 1490 *
BUCCIANTINI M ET AL.: "Prefibrillar amyloid protein aggregates share common features of cytotoxicity.", J BIOL CHEM., vol. 279, no. 30, 23 July 2004 (2004-07-23), pages 31374 - 31382 *
GLABE CG.: "Conformation-dependent antibodies target diseases of protein misfolding.", TRENDS BIOCHEM SCI., vol. 29, no. 10, October 2004 (2004-10-01), pages 542 - 547 *

Also Published As

Publication number Publication date
WO2010012004A2 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2010012004A3 (en) Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
WO2005025516A3 (en) Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
WO2008156622A8 (en) Humanized antibodies to amyloid beta
RU2657438C2 (en) Therapeutic agent or prophylactic agent for dementia
MX2009013503A (en) Monoclonal anti beta amyloid antibody.
WO2008060364A3 (en) Humani zed antibody against amyloid beta
WO2008011348A3 (en) Humanized antibody against amyloid beta
TW200732348A (en) Monoclonal antibody
AR066794A1 (en) UNION PROTEIN THAT INCLUDES AN ANION UNION DOMAIN THAT JOINS BETA AMILOIDE GLOBULOMERO (20-42), ANTIBODIES, NUCLEIC ACID MOLECULA CODIFYING VECTOR, CELL, GUEST CELL, METHOD AND PRODUCTION METHOD DIAGNOSIS
WO2010115843A3 (en) Pharmaceutical composition
MY164376A (en) Phosphospecific antibodies recognizing tau
MX341369B (en) Safe and functional humanized anti beta-amyloid antibody.
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
RU2017103446A (en) IMPROVED ANTIBODIES BINDING β-PROFIBRILLA
MX356800B (en) Humanized tau antibody.
EA201270813A1 (en) ANTIBODIES TO N3pGlu BETA AMYLOID PEPTIDE AND THEIR APPLICATION
WO2010144711A3 (en) Immunological targeting of pathological tau proteins
AR092779A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES ANTIBODIES THAT JOIN TAU PROTEIN CONFORMERS
WO2016201434A2 (en) Stable formulations of humanized anti-tau antibody
JO3188B1 (en) Antibody binding proteins specific to the serum isotope P component
CY1114604T1 (en) HUMANIZED ANTIBODY AGAINST AMYLOID BETA
UA102368C2 (en) SPECIFIC IN RELATION b-AMYLOID 1-42 MONOKLONAL'NI ANTIBODIES WHICH ARE THERAPEUTIC CHARACTERISTICS
AR107315A2 (en) HUMANIZED ANTIBODY
WO2009120659A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents
WO2009120657A3 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09801123

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13055908

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09801123

Country of ref document: EP

Kind code of ref document: A2